Stock Screener App

Frei -

Drug Manufacturers - Specialty & Generic

4.64

2.52% -0.12

Eagle Pharmaceuticals Inc (EGRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Eagle Pharmaceuticals Inc Aktie (EGRX) Neueste Nachrichten

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - ForexTV.com

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel ... - GlobeNewswire

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: - EIN News

Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates - Yahoo Movies Canada

Yahoo Movies Canada

Los Angeles Capital Management LLC Has $477000 Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now? - Yahoo News Australia

Yahoo News Australia

Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Below 200-Day Moving Average of $6.62 - MarketBeat

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Passes Below Two Hundred Day Moving Average of $6.62 - Defense World

Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Below 200-Day Moving Average of $6.62 - MarketBeat

Eagle Pharmaceuticals (EGRX) Surpasses Q4 Earnings and Revenue Estimates - Yahoo New Zealand News

Yahoo New Zealand News

Can Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Performance Keep Up Given Its Mixed Bag Of Fundamentals? - Yahoo Movies Canada

Yahoo Movies Canada

Heparin-Induced Thrombocytopenia (HIT) Treatment Market 2024 Revenue and Share Analysis | Pfizer Inc., Eagle ... - Motions Online

Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays - TipRanks.com - TipRanks

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

GlobeNewswire Inc.

Eagle Pharmaceuticals faces potential Nasdaq delisting - Investing.com India

Investing.com India

Eagle Pharmaceuticals Announces CFO Transition and Leadership Changes - TipRanks.com - TipRanks

Eagle Pharmaceuticals Announces CFO Transition and Leadership Changes - TipRanks.com - TipRanks

Eagle Pharmaceuticals announces workforce reduction By Investing.com - Investing.com

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before ... - PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals ... - PR Newswire

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender ... - GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle ... - GlobeNewswire

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

GlobeNewswire Inc.

Eagle Sues for Patent Damages From Rival Branded Cancer Drugs - Bloomberg Law

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender ... - GlobeNewswire

ROSEN, A LONGSTANDING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before ... - Markets Insider

Markets Insider

Eagle Pharmaceuticals (EGRX) Engaged in Accounting Fraud, Investor Suit Alleges - Hagens Berman - GlobeNewswire

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has ... - GlobeNewswire

Eagle Pharmaceuticals Allegedly Misled on Cancer Drug Revenue - Bloomberg Law

EGRX CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Eagle ... - Business Wire

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

GlobeNewswire Inc.

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate ... - Yahoo Finance

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq ... - GlobeNewswire

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Eagle Pharmaceuticals, Inc. on ... - Business Wire

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

EGRX Stock Quote Price and Forecast - CNN

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

GlobeNewswire Inc.

Eagle Pharmaceuticals Announces Management Change

GlobeNewswire Inc.

Eagle Pharmaceuticals CEO and Founder Scott Tarriff Retires - citybiz

Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

Zacks Investment Research

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround - Yahoo Finance

Eagle Delays Third Quarter 2023 Results and Conference Call - Yahoo Finance

TailorMed Partners with Eagle Pharmaceuticals to Streamline Patient Financial Assistance Enrollment - Business Wire

Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS - BioSpace

Eagle Pharmaceuticals Announces Phase 2 Study for Anti-Toxin Drug Candidate for SCABP - Infection Control Today

Infection Control Today

Eagle Pharmaceuticals: Going Through A Transition (NASDAQ:EGRX) - Seeking Alpha

$24.38

0.79%

$17.02

1.04%

$55.22

0.34%

$68.56

0.44%

$11.10

1.18%

$141.50

0.61%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen